Novo Nordisk A/S hired a new US chief charged with turning around the company’s most important market where mounting pricing pressure and intensifying competition are eroding its grip on the obesity-drug boom.
Jamey Millar joins the maker of Ozempic and Wegovy Thursday as executive vice president of US operations. He succeeds Dave Moore, who is leaving the company for personal reasons after just a year in the role.
Jamey Millar joins Novo Nordisk A/S as executive vice president of US Operations.
Source: Novo Nordisk A/S
Millar worked at UnitedHealth Group Inc., and prior to that had a two-decade career at GSK Plc.
“Although he is new to Novo Nordisk, he’s anything but new to our ...
